Trial reportCancer prevention research (Philadelphia, Pa.)2011
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.
Trial report in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- A Narrative Overview of Retinoid X Receptor Inhibitors in Chronic Disease Management.Current drug research reviews · 2025Review
- Onco-Ontogeny of Squamous Cell Cancer of the First Pharyngeal Arch Derivatives.International journal of molecular sciences · 2024Review
- Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?International journal of molecular sciences · 2021Review
- Retinoids as Chemo-Preventive and Molecular-Targeted Anti-Cancer Therapies.International journal of molecular sciences · 2021Review
- Polymorphic variants in the vitamin D pathway genes and the risk of ovarian cancer among non-carriers ofOncology letters · 2016Article
- Retinoid Chemoprevention: Who Can Benefit?Current pharmacology reports · 2015Article
- Pharmacogenomic analysis of retinoic-acid induced dyslipidemia in congenic rat model.Lipids in health and disease · 2014Article
- Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Headway and hurdles in the clinical development of dietary phytochemicals for cancer therapy and prevention: lessons learned from vitamin A derivatives.The AAPS journal · 2014Review
- Oral premalignancy: the roles of early detection and chemoprevention.Otolaryngologic clinics of North America · 2013Review
- Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.PloS one · 2013Article
- Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- The retinoid X receptors and their ligands.Biochimica et biophysica acta · 2012Review
- The BATTLE to personalize lung cancer prevention through reverse migration.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- Molecular cancer prevention: Current status and future directions.CA: a cancer journal for cliniciansReview
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) patients are at an increased risk of developing a second primary tumor (SPT) or recurrence following curative treatment. 13-cis-retinoic acid (13-cRA) has been tested in chemoprevention clinical trials, but the results have been inconclusive. We genotyped 9,465 single nucleotide polymorphisms (SNP) in 450 patients from the Retinoid Head and Neck Second Primary Trial. SNPs were analyzed for associations with SPT/recurrence in patients receiving placebo to identify prognosis markers and further analyzed for effects of 13-cRA in patients with these prognostic loci. Thirteen loci identified a majority subgroup of patients at a high risk of SPT/recurrence and in whom 13-cRA was protective. Patients carrying the common genotype of rs3118570 in the retinoid X receptor (RXRA) were at a 3.33-fold increased risk (95% CI, 1.67-6.67) and represented more than 70% of the study population. This locus also identified individuals who received benefit from chemoprevention with a 38% reduced risk (95% CI, 0.43-0.90). Analyses of cumulative effect and potential gene-gene interactions also implicated CDC25C:rs6596428 and JAK2:rs1887427 as 2 other genetic loci with major roles in prognosis and 13-cRA response. Patients with all 3 common genotypes had a 76% reduction in SPT/recurrence (95% CI, 0.093-0.64) following 13-cRA chemoprevention. Carriers of these common genotypes constituted a substantial percentage of the study population, indicating that a pharmacogenetic approach could help select patients for 13-cRA chemoprevention. The lack of any alternatives for reducing risk in these patients highlights the need for future clinical trials to prospectively validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.